MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2025.114376

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2025

Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate.

Li Shunyi, Huo Shengyuan, Zheng Wanru, Wu Shipo, Chen Yi, Zhang Zhe, Wang Busen, Zhao Zhenghao, Huo Nan, Xu Jinghan, Liu Tianyu, Long Jianglan, Song Xiaohong, Zhang Jinlong, Dan Junyan, Zhang Mengyao, Hou Lihua

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Conventional intramuscular vaccines are unable to elicit robust mucosal immunity which is essential for preventing respiratory pathogens like SARS-CoV-2. To overcome this limitation, we developed an oral delivery platform based on coacervate formation (termed THT) through the electrostatic self-assembly of hyaluronic acid (HA) and trimethyl chitosan (TC) for the efficient oral delivery of adenovirus type 5-vectored COVID-19 vaccine (Ad5-nCoV) and protein antigens. THT coacervates shielded payloads from gastrointestinal degradation while simultaneously enhancing dendritic cell uptake and promoting dendritic cell maturation in vitro. Subsequent murine model studies demonstrated that oral vaccination with THT induced sustained systemic IgG and neutralizing antibody titers comparable to those achieved via intramuscular injection. Notably, this oral strategy uniquely elicited potent gut-mucosal secretory IgA responses, which was entirely absent in the intramuscular injection groups. The THT platform also generated durable memory T cell populations and spike-specific memory B cell reservoirs that persisted for over 180 days post-boost. These cross-mucosal immune responses collectively conferred significant protection against SARS-CoV-2 virus challenge. Importantly, TC/HA coacervates similarly enhanced protein antigen immunogenicity, inducting robust humoral and mucosal immunity. Therefore, we established the THT coacervate as a highly promising and widely applicable oral platform to generate protective systemic and mucosal immunity against respiratory viral infections.

Для цитирования: Li Shunyi, Huo Shengyuan, Zheng Wanru, Wu Shipo, Chen Yi, Zhang Zhe, Wang Busen, Zhao Zhenghao, Huo Nan, Xu Jinghan, Liu Tianyu, Long Jianglan, Song Xiaohong, Zhang Jinlong, Dan Junyan, Zhang Mengyao, Hou Lihua. Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate.. Journal of controlled release : official journal of the Controlled Release Society. 2025. DOI: 10.1016/j.jconrel.2025.114376.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.